One-Sentence Summary of Key Findings: Apollomics (APLM) is a small clinical-stage oncology biotech with a focused pipeline led by Phase 2 asset vebreltinib (APL-101), minimal revenue from partnerships, ongoing Nasdaq compliance challenges, highly volatile stock performance, and very limited Wall Street coverage reflecting its high-risk pre-commercial status.
Interpretation: The outsized 1-year gains reflect recovery from lows amid clinical updates and financings, but the wide range and low volume indicate speculative trading rather than fundamental stability.
Limitation: Historical returns include effects of corporate actions (e.g., SPAC merger as Maxpro Capital Acquisition Corp.); past performance is not indicative of future results. Data as of mid-July 2026 snapshots.
| Metric | Value | Notes |
|---|---|---|
| Revenue (TTM) | $8.84 million | Likely licensing/milestone income (e.g., Asia rights deals); not product sales. |
| Net Income (TTM) | -$10.94 million | Operating losses typical of clinical-stage biotech. |
| EPS (TTM, diluted) | -$7.57 | High per-share loss due to low share count post-corporate actions. |
| Profit Margin | -123.7% | Deeply negative as expected pre-revenue. |
| Cash (most recent quarter) | $3.28 million | Limited runway; supplemented by bridge financing. |
| Market Cap | ~$42–44 million | Micro-cap classification. |
| Return on Equity (TTM) | -1,305% | Extremely negative due to accumulated losses. |
| Return on Assets (TTM) | -57.6% | Inefficient asset utilization in R&D phase. |
Limitation/Assumption: Financial data primarily from Yahoo Finance and company press releases as of July 2026; full audited statements available in SEC filings (Form 20-F). No product revenue; sustainability depends on future partnerships, clinical success, or dilutive financings. Share count and EPS impacted by potential reverse splits or equity issuances common in this sector.
More Information: Yahoo Finance APLM | Company IR Site | Macrotrends Financials
| Metric | Details |
|---|---|
| Consensus Rating | Sell (based on 1 analyst) |
| Number of Analysts (last 12 months) | 1 (Weiss Ratings) |
| Recent Action | Downgrade to Sell (E+) on June 23, 2026 |
| Price Targets | Limited/recently unavailable; older targets (2023) ranged ~$8.50 consensus with highs to $17 |
Uncertainty: Analyst coverage is extremely sparse; ratings can change rapidly with clinical data or financing news. No broad consensus from major firms.
Limitation: Data from MarketBeat and similar aggregators; always verify latest reports directly as coverage may be outdated or issuer-specific.
More Information: MarketBeat APLM Forecast | Yahoo Analyst Section
Interpretation: Revenue is partnership-driven; success hinges on advancing pipeline to attract bigger pharma partners for global development/commercialization.
Primary peers in oncology biopharma (MET inhibitors, immuno-oncology, AML/solid tumor focus):
| Company | Ticker/Example Focus | Notes |
|---|---|---|
| AbbVie | ABBV | Large-cap oncology leader with targeted therapies and IO. |
| Amgen | AMGN | Established player in targeted cancer treatments. |
| Gilead Sciences | GILD | Strong in oncology and antivirals with IO pipeline. |
| Vertex Pharmaceuticals | VRTX | Precision medicine focus (though more cystic fibrosis historically). |
| Regeneron | REGN | IO and antibody expertise. |
| argenx | ARGX | Emerging biotech with antibody platforms. |
| Smaller peers | e.g., ARMP, BYSI, INMB | Similar micro-cap oncology or biotech plays. |
Interpretation: APLM competes in a crowded oncology space where larger players have resources for combination therapies and global trials; differentiation relies on specific MET targeting and early IO assets.
Limitation: Competitor list is illustrative based on sector overlap; direct head-to-head clinical comparisons are limited. Market dynamics shift with new trial data or M&A.
More Information: Financhill Peer Comparison | Company Pipeline Page
Uncertainty: Clinical development success rates in oncology are historically low (~10–20% from Phase 1 to approval); partnership and funding outcomes are unpredictable.
Limitation: Pipeline status based on company disclosures and news up to mid-2026; always cross-reference latest clinicaltrials.gov or press releases for updates. No guarantee of future milestones.
More Information: Official Website | IR News Releases | Yahoo Company Profile